| Bioactivity | AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research[1]. |
| CAS | 2848560-66-5 |
| Formula | C21H21F2N3O5 |
| Molar Mass | 433.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gotchev D, et al. Structure-Activity Relationships and Discovery of (S)-5-(tert-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. J Med Chem. 2024 Nov 28;67(22):20467-20494. |
AB-161
CAS: 2848560-66-5 F: C21H21F2N3O5 W: 433.41
AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. A
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.